Tazarotene 0.045% Lotion for Moderate-to-Severe Acne in Male and Female Participants: A Phase II Post-hoc Analysis

CLINICAL TRIALS ID: NCT02938494 BACKGROUND: In a Phase II study, tazarotene 0.045% lotion was statistically superior to vehicle and comparable to tazarotene 0.1% cream in reducing acne lesions, with fewer treatment-related adverse events (TEAEs) than the cream. OBJECTIVE: We analyzed data from the a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Aesthet Dermatol
Main Authors: Baldwin, Hilary E., Green, Lawrence J., Kircik, Leon, Guenin, Eric Pierre, Forest, Anya Loncaric, Pillai, Radhakrishnan
Formato: Artigo
Idioma:Inglês
Publicado em: Matrix Medical Communications 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8142831/
https://ncbi.nlm.nih.gov/pubmed/34055190
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados